Premium
Pregnancy‐associated glycoprotein (α 2 ‐pag) ‐ A possible marker in breast cancer?
Author(s) -
Wilking Nils,
Carlström Kjell,
Gustafsson Sven A.,
Karnström Leif,
Schoultz Bo Von
Publication year - 1984
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910340408
Subject(s) - breast cancer , alpha (finance) , medicine , estrogen receptor , correlation , tumor marker , mammary gland , cancer , estrogen , pregnancy , stage (stratigraphy) , endocrinology , glycoprotein , positive correlation , beta (programming language) , oncology , biology , paleontology , construct validity , genetics , geometry , mathematics , microbiology and biotechnology , computer science , patient satisfaction , programming language , nursing
Serum levels of pregnancy‐associated α‐glycoprotein (α 2 ‐PAG) and estradiol‐17β (E 2 ) and the estrogen receptor content (ER) in the tumor cytosol were measured in 174 women aged 24 to 94 years with primary breast cancer and the values were related to patient age, tumor size and clinical stage. While E 2 , levels were significantly lower and ER values significantly higher in older women, no significant correlation was found between α‐PAG on one hand and the patients' age, E 2 , or ER values or tumor size on the other. A significant positive correlation (p= 0.016, Pearson correlation test) was found between α 2 ‐PAG values and the clinical stage of the tumor. The results suggest the possible use of α 2 ‐PAG as a marker for the monitoring of disseminated breast cancer during systemic therapy.